WeChat· 医疗器械商业评论·· 22 hours agoPickScore82
TRIC-I-HF: Transcatheter Tricuspid Repair Cuts 3-Year Death or Heart Failure Hospitalization Risk by 60% Versus Medication Alone
In brief
The TRIC-I-HF trial showed that transcatheter tricuspid valve repair combined with medication reduced the risk of death or heart failure hospitalization at 3 years by 60% compared with medication alone in 360 high-risk patients (HR 0.40, NCT04634266).
Why it matters
The original compares TRIC-I-HF with TRI-FR and TRILUMINATE, showing that enrolling a high-risk population explains why hard endpoints separated for the first time.
Source: WeChat · mp.weixin.qq.com